ArticleJACC. Heart failure2026
Ex Vivo Perfusion Unmasks a Proteomic Signature of Primary Graft Dysfunction in Donor Hearts.
Article in JACC. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrimary graft dysfunction (PGD) remains the leading cause of early mortality after heart transplantation and limits broader adoption of donation after circulatory death (DCD) hearts. Ex vivo heart perfusion (EVHP) provides a human platform to characterize molecular features associated with graft performance.
objectivesThis study examines the circulating proteome during EVHP to determine potential markers or modulators of PGD in DCD hearts.
methodsThe authors prospectively studied 37 human DCD hearts supported on EVHP. Perfusate was sampled at initiation (0-2 hours) and termination (3-6 hours) and profiled using a high-throughput proteomic platform (SOMAScan 11K). Ten PGD cases were propensity-matched to 10 non-PGD controls. Differential protein abundance and pathway enrichment analyses were performed.
resultsAt EVHP initiation, PGD hearts demonstrated enrichment of senescence-associated pathways (normalized enrichment score [NES]: 1.93; q < 0.01). By EVHP termination, proteomic profiles more clearly separated PGD from non-PGD hearts. PGD hearts exhibited broader proteomic remodeling, with 1,242 increased proteins (742 unique; q < 0.05) and 745 decreased proteins (619 unique; q < 0.05). Protein abundance was more dynamically associated with perfusion time in PGD hearts (33 proteins; median |ρ| = 0.78; q < 0.05) than in non-PGD hearts (3 proteins; median |ρ| = 0.83; q < 0.05). Pathway analysis revealed enrichment of apoptotic (NES: 1.75; q < 0.05) and catabolic programs (NES: 1.42; q < 0.05), with concurrent activation of inflammatory pathways (NES: 1.68; q < 0.05) in hearts destined to have PGD.
conclusionsPGD is defined less by baseline differences than by divergent proteomic trajectories during EVHP. Early enrichment of senescence-associated pathways is followed by coordinated activation of apoptotic and catabolic programs. These findings position EVHP as a physiological window for identifying molecular signatures of graft dysfunction and suggest an opportunity for targeted intervention in DCD donor hearts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.